Recent developments in glycine antagonists

Bibliography

• WATKINS JC, EVANS RH: Excitatory amino acid. Ann. Rev. Pharmacol. Toxicol. (1981) 21:165–204.
   PubMed Web of Science ®Google Scholar
• MONAGHAN DT, BRIDGES RJ, COTMAN CW: The excita-tory amino acid receptors: their classes, pharma-cology and distinct properties in the function of the central nervous system. Ann. Rev. Pharmacol. Toxicol. (1989) 29:365–402
   PubMed Web of Science ®Google Scholar
• MELDRUM B: Protection against ischemic neuronal damage by drugs acting on excitatory neurotransmit-ters. Cerebrovasc. Brain Metab. Rev. (1990) 2:27–57
   PubMedGoogle Scholar
• MCCULLOGH J: Excitatory amino acid antagonists and their potential for the treatment of ischemic brain damage in man. Br. J. Clin. Pharmacol (1992) 34:106–114
   PubMed Web of Science ®Google Scholar
• SCHEHR RS: New treatments for acute stroke. Nature Biotech. (1996) 14:1549–1554
   PubMed Web of Science ®Google Scholar
• MELDRUM B: Excitatory amino acid antagonists. (1991) Blackwells, Oxford, UK.
   Google Scholar
• •One of the main textbooks for learning the complexity of the neurotransmitters.
   Google Scholar
• COLLINGRIDGE GL, WATKINS JC: The NMDA receptor. 2nd. (1994) IRL Press, Oxford, UK.
   Google Scholar
• •The right introduction for entering the world of the NMDA receptor.
   Google Scholar
• LOSCHER W: Pharmacology of glutamate receptor antagonists in the kindling model of epilepsy. Prog. Neurobiol (Oxford) (1998) 54:721–741.
   PubMed Web of Science ®Google Scholar
• JOHNSON JW, ASHER P: Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature (1987) 325:529–531.
   PubMed Web of Science ®Google Scholar
• •The first article reporting the role of glycine in the potentia-tion of the NMDA receptor.
   Google Scholar
• KLECKNER NW, DINGLEDINE R: Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science (1988) 241:835–837.
   PubMed Web of Science ®Google Scholar
• MORRIS RG, ANDERSON ME, LYNCH GS, BAUDRY M: Selective impairment of learning and blockade of long-term potentiation by an N-methyl-D-aspartate receptor antagonist, AP5. Nature (1986) 319:774–776.
   PubMed Web of Science ®Google Scholar
• PALEFREYMAN MG, BARON MB: Non-competitive NMDA antagonists, acting on the glycine site. In: Excita-tory Amino Add Antagonists. (1991) Blackwells, Oxford UK:101–129.
   Google Scholar
• CARTER AJ: Regulation of the NMDA receptor-channel complex by the strycnine-insensitive glycine site. Drugs Future (1992) 17:595–613.
   Google Scholar
• KEMP JA, LEESON PD: The glycine site of the NMDA receptor-five years on. Trends Pharmacological Sci. (1993) 14:20–25.
   PubMed Web of Science ®Google Scholar
• IVERSEN LL, KEMP JA: Non competitive NMDA antago-nists as drugs In: The NMDA Receptor. 2nd Edition. (1994) IRL Press, Oxford UK:469–486.
   Google Scholar
• LEESON PD, IVERSEN LL: The glycine site on the NMDAreceptor: structure - activity relationships and therapeutic potential. J. Med. Chem. (1994) 37:4053–4067.
   PubMed Web of Science ®Google Scholar
• •A very detailed review covering the field until 1994.
   Google Scholar
• DANNHARDT G, KOHL BK: The glycine site on the NMDA receptor: structure-activity relationships and possible therapeutic applications. Curr. Med. Chem. (1998) 5:253–263.
   PubMed Web of Science ®Google Scholar
• TRANQUILLINI ME, REGGIANI A: Glycine-site antago-nists and stroke. Exp. Opin. Invest. Drugs. (1999) 8:1837–1848
   PubMedGoogle Scholar
• •Interesting review covering the application of different glycine antagonists for the treatment of stroke
   Google Scholar
• MICHELI F, PASQUARELLO A: Glycine antagonists for treatment of stroke: a literature survey (1997-1999). Curr. Opin. Cardio. Pulm. Renal Invest. Drugs (1999) 1:565–575.
   Google Scholar
• •A review covering the application of different glycine antagonists for the treatment of stroke and an update on the of many products (from preclinical development to Phase III).
   Google Scholar
• WOODWARD RM, HUETTNER JE, TRAN M, GUASTELLA J,KEANA JFW, WEBER E: Pharmacology of 5-chloro-7-trifluoromethy1-1,4-dihydro-2,3-quinoxalinedione: a novel systemically active ionotropic glutamate receptor antagonist. J. Pharmacol. Exp. Ther. (1995) 275:1209–1218.
   PubMed Web of Science ®Google Scholar
• LUTFY K, DOAN P, WEBER E: ACEA-1328, an NMDA receptor antagonist, increases the potency of morphine and U50,48811 in the tail flick test in mice. Pharmacol. Res. (1998) 38:453–460.
   PubMed Web of Science ®Google Scholar
• LUTFY K, DOAN P, WEBER E: ACEA-1328, a NMDA receptor/glycine site antagonist, acutely potentiates antinociception and chronically attenuates tolerance induced by morphine. Pharmacol. Res. (1999) 40:435–442.
   PubMed Web of Science ®Google Scholar
• ACKLIN P, ALLGEIER H, AUBERSON Y et al.:5-Aminomethylquinoxaline-2,3-diones, part III: arylamide derivatives as highly potent and selective glycine-site NMDA receptor antagonists. Bioorg. Med. Chem. Lett. (1998) 8:493–498.
   PubMed Web of Science ®Google Scholar
• AUBERSON YP, ACKLIN P, ALLGEIER H et al.:5-Aminomethylquinoxaline-2,3-diones, part II: N-arylamide derivatives as novel NMDA/glycine and AMPA antagonists. Bioorg. Med. Chem. Lett. (1998) 8:71–74.
   PubMed Web of Science ®Google Scholar
• ZHOU Z-L, KHER SM, CAI SX, ESPITIA SA, HAWKINSON JE,KEANA JFW: Synthesis and SAR of novel di- and trisub-stituted 1,4-dihydroquinoxaline-2,3-diones related to licostinel (Area 1021) as nmda/glycine site antago-nists. 216th ACS National Meeting, Boston, 23–27 August 1998 MEDI-112 (Abstract).
   Google Scholar
• AUBERSON YP, ACKLIN P, BISHOFF S et al.: N-Phosphonoalky1-5-aminomethylquinoxaline -2,3-diones: in vivo active AMPA and NMDA (glycine) antagonists. Bioorg. Med. Chem. Lett (1999) 9:249–254.
   PubMed Web of Science ®Google Scholar
• STOBIE A: New Medicines from Heterocycles. Royal Society of Chemistry Meeting, London, UK (11 November 1999) (Abstract).
   Google Scholar
• CAI SX, HUANG JC, ESPITIA SA et al.: 5-(N-Oxyaza)-7-substituted-1,4-dihydroquinoxaline-2, 3-diones: novel, systemically active and broad spectrum antagonists for NMDA/glycine, AMPA and kainate receptors. J. Med. Chem. (1997) 40:3679–3686.
   PubMed Web of Science ®Google Scholar
• CUGOLA A, DONATI D, GUARNERI M et al.: Synthesisand biological evaluation of pyrido[2,3-b]pyrazine and pyrido[2,3-b]pyrazine-N-oxide as selective glycine antagonists. Bioorg. Med. Chem. Lett. (1996) 6:2749–2754.
   Web of Science ®Google Scholar
• MICHELI F, CUGOLA A, DONATI D et al.:2,3-Dihydro-6,7-dichloro-pyrido[2,3-b]pyrazine-8-oxide as selective glycine antagonist with in vivo activity. Bioorg. Med. Chem. (1997) 5:2129–2132.
   PubMed Web of Science ®Google Scholar
• DI FABIO R, CAPELLI AM, CONTI N et al. Substituted-2-carboxylates as in vivo potent antagonists acting at the strychnine-insensitive glycine binding site. J. Med. Chem. (1997) 40:841–850
   PubMed Web of Science ®Google Scholar
• NICHOLS AC, YIELDING KL: Anticonvulsant activity of 4-urea-5,7-dichlorokynurenic acid derivatives that are antagonists at the NMDA-associated glycine binding site. Mol. Chem. Neuropathol. (1999) 35:1–12.
   Google Scholar